文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

脓毒症与2019冠状病毒病:共同特征与抗炎治疗策略

Sepsis and Coronavirus Disease 2019: Common Features and Anti-Inflammatory Therapeutic Approaches.
PubMed 文献 · Crit Care Med · 2020-01-01
一句话结论重症COVID-19与脓毒症共享高炎症和凝血病特征,多数ICU死亡由病毒性脓毒症所致,抗炎治疗可借鉴脓毒症经验。

本文为综述,指出全球正努力识别重症感染患者的特定临床特征,包括血管功能障碍、血栓形成、炎症失调和呼吸系统并发症。近期COVID-19与脓毒症密切相关,提示多数ICU死亡由病毒性脓毒症所致。尽管COVID-19患者免疫和炎症状态的代表性数据尚不完全清楚,但高炎症和凝血病明显促进疾病严重程度。本文呈现重症COVID-19与脓毒症的共同特征,并描述先前已在脓毒症中评估过的、针对COVID-19提出的抗炎治疗。

要点

  • 重症COVID-19与脓毒症共享血管功能障碍、血栓形成、炎症失调和呼吸系统并发症等特征。
  • COVID-19与脓毒症密切相关,提示多数ICU死亡由病毒性脓毒症所致。
  • 高炎症和凝血病促进COVID-19疾病严重程度。
  • 本文描述先前已在脓毒症中评估过的、针对COVID-19提出的抗炎治疗。

适用人群与场景

  • 感染重症患者,包括重症COVID-19患者和脓毒症患者。

处置流程与药物剂量

  • 描述先前已在脓毒症中评估过的、针对COVID-19提出的抗炎治疗。

研究设计与关键结果

  • 综述指出重症COVID-19与脓毒症共享血管功能障碍、血栓形成、炎症失调和呼吸系统并发症等特征。
  • COVID-19与脓毒症密切相关,提示多数ICU死亡由病毒性脓毒症所致。
  • 高炎症和凝血病促进疾病严重程度。

证据类型、等级与局限

  • 证据类型:综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为理解重症急性呼吸综合征冠状病毒2感染后导致脓毒症的病理生理学是当前临床需求,以改进应用于重症患者的重症监护治疗。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Great efforts are being made worldwide to identify the specific clinical characteristics of infected critically ill patients that mediate the associated pathogenesis, including vascular dysfunction, thrombosis, dysregulated inflammation, and respiratory complications. Recently, coronavirus disease 2019 has been closely related to sepsis, which suggests that most deaths in ICUs in infected patients are produced by viral sepsis. Understanding the physiopathology of the disease that lead to sepsis after severe acute respiratory syndrome coronavirus 2 infection is a current clinical need to improve intensive care-applied therapies applied to critically ill patients. Although the whole representative data characterizing the immune and inflammatory status in coronavirus disease 2019 patients are not completely known, it is clear that hyperinflammation and coagulopathy contribute to disease severity. Here, we present some common features shared by severe coronavirus disease 2019 patients and sepsis and describe proposed anti-inflammatory therapies for coronavirus disease 2019 which have been previously evaluated in sepsis.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Beltrán-García J, Osca-Verdegal R, Pallardó FV, et al. Sepsis and Coronavirus Disease 2019: Common Features and Anti-Inflammatory Therapeutic Approaches. Crit Care Med. 2020. PMID: 32826431. doi:10.1097/CCM.0000000000004625

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。